The brief
- Policybazaar and Turtlemint are facing pressure in health-insurance distribution
- Insurance distribution competition may affect PB Fintech’s Policybazaar business
- Should you buy PB Fintech, Turtlemint after nearly 40% crash in two days?
- New-Age Tech Stocks: Insurtech Sell-Off Drags Combined M-Cap Down By $3.6 Bn This Week
- Turtlemint Crashes Another 20%, PB Fintech Falls 8% On IRDAI’s Proposed Commission Caps
- Insurance distributors bleed as Irdai proposes sharp commission cuts
- PB Fintech, Turtlemint hit hard as Irdai commission overhaul pressures business models